ReviewInternational ophthalmology2025
Exploring the ocular involvement in multiple myeloma: a comprehensive review of 70-year clinical studies.
Review in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo review the ocular symptoms and the related physiopathology in patients diagnosed with multiple myeloma (MM) to evaluate whether the ocular manifestations can be considered a disease hallmark that can guide the clinician's decision-making.
methodsA comprehensive review of three databases (PubMed, Scopus, Embase) was conducted until April 25, 2024. Studies reporting intra- or extraocular manifestations of MM were included, excluding cases of other monoclonal gammopathies or therapy-related ocular effects. After screening 1873 initial results and hand-searching references, 82 articles were included.
resultsOphthalmic manifestations may be the first sign or represent MM relapsing. Several eyelid manifestations have been reported, including bilateral eyelid ecchymosis, cutaneous xanthomatosis, necrobiotic xanthogranuloma, localized lipid deposits, ptosis associated with diplopia, and eyelid ectropion. Several reports have reported crystalline deposits throughout all layers of the cornea, including the epithelium, stroma, and endothelium of MM patients. In addition, copper deposition that appears as a greenish-brown deposit affecting the central cornea on Descemet's membrane with unique characteristics has also been rarely reported in MM patients. Beyond anterior segment involvement, the retina and choroid can also be affected in MM with bilateral central retinal vein occlusion, choroidal effusion, ciliary body cysts, Purtscher's retinopathy, and microvascular changes.
conclusionsEarly recognition of MM's ophthalmic manifestations is essential to establish an early diagnosis and treatment. Hence, all patients diagnosed with MM should undergo a thorough ophthalmic examination. Therefore, a close collaboration between hematologists and ophthalmologists could lead to earlier diagnoses and potentially impact the course of the disease.
Indexed as
Identifiers
40085267What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.